Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Olmesartan medoxomil + amlodipine + hydrochlorothiazide is a fixed-dose combination medication used to treat high blood pressure (hypertension). It contains three active ingredients: - Olmesartan medoxomil, an angiotensin II receptor blocker (ARB), which blocks the action of angiotensin II and relaxes blood vessels. - Amlodipine, a calcium channel blocker (CCB), which inhibits calcium influx into vascular smooth muscle and cardiac muscle, leading to vasodilation. - Hydrochlorothiazide, a thiazide diuretic that increases urine output by inhibiting sodium reabsorption in the distal tubules of the kidney. This combination lowers blood pressure through complementary mechanisms—vasodilation and reduction of fluid volume. The drug is taken orally and is indicated for patients whose hypertension is not adequately controlled with monotherapy or dual therapy[1][3][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on olmesartan medoxomil + amlodipine + hydrochlorothiazide.